Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine hydrochloride + isopropyl alcohol + methylprednisolone acetate + povidone-iodine is an Rx-only combination injection kit marketed under the Dyural L Kit brand family. The therapeutically relevant component is **methylprednisolone acetate**, a depot synthetic glucocorticoid corticosteroid suspension used for intramuscular, intra-articular, soft tissue, and intralesional administration to deliver anti-inflammatory and immunosuppressive effects primarily through activation of the glucocorticoid receptor. **Lidocaine hydrochloride** provides local anesthetic activity, while **povidone-iodine** and **isopropyl alcohol** function as antiseptic skin-preparation components included in the kit rather than core systemic therapeutic agents. The kit has been listed in DailyMed as an unapproved drug product whose labeling has not been approved by the FDA, and it is associated with broad labeled corticosteroid uses across allergic, rheumatologic, dermatologic, hematologic, endocrine, neurologic, pulmonary, renal, gastrointestinal, ophthalmic, and soft-tissue inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine hydrochloride + isopropyl alcohol + methylprednisolone acetate + povidone-iodine.